Global Pneumococcal Vaccine Market Trends 2020 | Segmentation, Outlook, Industry Report to 2026
The global pneumococcal vaccine market is forecast to grow at a CAGR of nearly 4.0% during the forecast period. Increasing individual, governmental, and international organization expenditure on the pneumococcal vaccine to curb the pneumonia is a major factor for the growth of the market in the near future. Few market players have a major market share in the pneumococcal vaccine all across the globe which includes Pfizer Inc., Sanofi SA, and GlaxoSmithKline PLC.
To Request a Sample of our Global Pneumococcal
Vaccine Market: https://www.omrglobal.com/request-sample/pneumococcal-vaccine-market
Pfizer is the market leader in the pneumococcal vaccine market.
The company offers the pneumococcal vaccine under the brand name Prevnar 13. It
first got the European Union approval in December 2009 and then the US FDA
approval in February 2010. In 2019, the company generated $5.8 billion from the
sales of Prevnar 13. Out of the total revenue, around $3.2 billion was
generated from the US alone.
Merck & Co., Inc. is another major company offering vaccines
all across the globe. The company offers Pneumovax 23. The vaccine has
generated revenue of $926 million in 2019 as compared to $907 million and $821
million in 2018 and 2017 respectively. GlaxoSmithKline PLC is another major
player in the pneumococcal vaccine. The company is offering Synflorix against
pneumonia all across the globe except the US. The vaccine has generated revenue
of more than $580 million in 2019 compared to more than $430 million in 2018.
The company also offers its vaccines to 10 Gavi-eligible countries at a
discounted price. The company has pledged to deliver 720 million doses of
Synflorix.
However, new players are also entering the market which can end
the monopoly of the companies in the global market. For instance, in January
2020, a Chinese company Walvax Biotechnology Co., Ltd. got the pneumococcal
13-valent conjugate vaccine approval from the National Medical Products
Administration. It is the first pneumococcal 13-valent conjugate vaccine
developed which can affect the revenue of Pfizer Inc. In 2018, about 3.85
million doses of Prevnar 13 were sold in China whereas Walva is planning to
produce around 30 million doses in a year. Moreover, in December 2019, India
based Serum Institute of India also developed a 10-valent pneumococcal vaccine
and got WHO approvals.
However, the major players are also significantly working to
develop new products. For instance, Pfizer Inc. is working to develop a vaccine
against all 20 serotypes of pneumonia disease. Merck & Co., Inc. is also
working on the V114 polyvalent conjugate 15-valent pneumococcal vaccine. Phase
3 of the vaccine was initiated in June 2018 in adults over 50 years and on
pediatric were initiated in October 2018. In June 2020, the company got success
in two phases 3 trials of the vaccine. Due to multiple activities, a
considerable disruption in the revenue of the companies will be witnessed in
the near future which are dealing in the pneumococcal vaccine industry.
(Get 15% Discount on Buying this Report)
A full
Report of Global Pneumococcal Vaccine Market is Available at: https://www.omrglobal.com/industry-reports/pneumococcal-vaccine-market
Global Pneumococcal Vaccine Market- Segmentation
By Vaccine Type
- Pneumococcal Conjugate Vaccine
(PCV13)
- Pneumococcal Polysaccharide
Vaccine (PPSV23)
- Others
By Distribution Channel
- Public
- Private
By Type
- Branded
- Generic
By Age Group
- Children
- Adult
Global Pneumococcal Vaccine Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
Company Profiles
·
Astellas Pharma Inc.
·
China National Biotec Group Company Ltd.
·
CSL Ltd.
·
GlaxoSmithKline PLC
·
Merck & Co., Inc.
·
Novavax, Inc.
·
Pfizer Inc.
·
Walvax Biotechnology Co., Ltd.
·
SK Bioscience
·
Sanofi SA
·
Serum Institute of India Pvt. Ltd.
·
PnuVax Incorporated
Reasons to Buying
From us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pneumococcal-vaccine-market
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market
Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment